A Case of Central Diabetes Insipidus: Evaluation in Pregnancy
Copyright © 2011 SciRes. IJCM
280
there aren’t changes compared to previous situation and
it’s not necessary to adapt dosage of desmopressin. Our
patient, in fact, required a slightly higher dose of des-
mopressin in the first trimester. Contrary to expectation,
the need of desmopressin did not increase during the
weeks, allowing an easy management in the administra-
tion of the drugs.
The primary aim of the therapy is the control of nic-
turia, using the lowest dosage possible of desmopressin,
followed by a daytime dose for the control of daytime
diuresis. It’s also important to maintain water intake at
1000 mL for day.
Safety in administration of desmopressin in pregnancy
is nowadays testing because of lack of controlled studies
regarding pregnant women treated. Available studies
agree on the safety of the drugs for maternal and fetal
outcome and show an incidence of fetal malformations,
Down syndrome, intrauterin growth retardation, low
birth weight or neonatal death comparable to uncompli-
cated pregnancies. Preeclampsia has been documented
in few cases and there aren’t described severe cases of
hypertension of the pregnant. This finding confirms the
lack of effect of vasoconstriction of desmopressin. As
observed in our case, ossitocino-like effects of this drug,
which can lead to preterm delivery, are not reported.
REFERENCES
[1] M. C. Hime and J. C. Richardson, “Diabetes Insipidus
and Pregnancy: Case Report, Incidence and Review of
Literature,” Obstetrical Gynecological Survey, Vol. 33,
No. 6, 1978, pp. 375-379.
doi:10.1097/00006254-197806000-00001
[2] M. D. Sonia Ananthakrishnan, “Diabetes Insipidus in
Pregnancy: Etiology, Evaluation and Management,”
American Association of Clinical Endocrinologists, Vol.
15, 2009, pp. 377-382.
[3] R. W. Schrier, “Systemic Arterial Vasodilatation, Vaso-
pressin, and Vasopresinase in Pregnancy,” Journal of
American Society of Nephrology, Vol. 21, No. 4, 2010, pp.
570-572.
[4] J. M. Davison, E. A. Sheills, P. R. Phillips and M. D.
Lindheimer, “Serial Evaluation of Vasopressin Release
and Thirst in Human Pregnancy. Role of Human Chori-
onic Gonadotrophin in the Osmoregulatory Changes of
Gestation,” The Journal of Clinical Investigation, Vol. 81,
No. 3, 1988, pp. 798-806. doi:10.1172/JCI113386
[5] J. M. Davison, E. A. Gilmore, J. Dürr, G. L. Robertson
and M. D. Lindheimer, “Altered Osmotic Thresholds for
Vasopressin Secretion and Thirst in Human Pregnancy,”
American Journal of Physiology, Vol. 246, No. 1, 1984,
pp. F105-F109.
[6] M. D. Lindheimer, W. M. Barron and J. M. Davison,
“Osmoregulation of Thirst and Vasopressin Release in
Pregnancy,” American Journal of Physiology, Vol. 257,
No. 2, 1989, pp. F159-F169
[7] M. D. Lindheimer, “Polyuria and Pregnancy: Its Cause,
Its Danger,” Obstetrics & Gynecology, Vol. 105, No. 5,
2005, pp. 1171-1172.
doi:10.1097/01.AOG.0000162538.95869.05
[8] J. M. Davison, E. A. Sheills, P. R. Philips, W. M. Barron
and M. D. Lindheimer, “Metabolic Clearance of Vaso-
pressin and an Analogue Resistant to Vasopressinase in
Human Pregnancy,” American Journal of Physiology,
Vol. 264, No. 2, 1993, pp. F348-F353.
[9] Y. Iwasaki, Y. Oiso, K. Kondo, et al., “Aggravation of
Subclinical Diabetes Insipidus during Pregnancy,” New
England Journal of Medicine, Vol. 324, No. 8, 1991, pp.
522-526. doi:10.1056/NEJM199102213240803
[10] Y. Hamai, T. Fujuu, H. Nishina, S. Kozuma, H. Yoshi-
kawa and Y. Taketani, “Differential Clinical Course of
Pregnancies Complicated by Diabetes Insipidus Which
Does, or Does Not Pre-date the Pregnancy,” Human Re-
production, Vol. 2, No. 8, 1997, pp. 1816-1818.
doi:10.1093/humrep/12.8.1816
[11] J. A Dürr, “Diabetes Insipidus in Pregnancy,” American
Journal of Kidney Diseases, Vol. 9, No. 4, 1987, pp.
276-283.
[12] U. C. Brewster and J. P. Hayslett, “Diabetes Insipidus in
the Third Trimester of Pregnancy,” Obstetrics & Gyne-
cology, Vol. 105, No. 5, 2005, pp. 1173-1176.
doi:10.1097/01.AOG.0000161811.02155.68
[13] B. A. Källén, S. S. Carlsson and B. K. Bengtsson, “Dia-
betes Insipidus and Use of Desmopressin (Minirin) during
Pregnancy,” European Journal Endocrinology, Vol. 132,
No. 2, 1995, pp. 144-146.
[14] J. G. Ray, “DDAVP Use during Pregnancy: An Analysis
of Its Safety for Mother and Child,” Obstetrical & Gyne-
cological Survey, Vol. 53, No. 7, 1998, pp. 450-455.
doi:10.1097/00006254-199807000-00025
[15] S. Hjartardottir, B. G. Leifsson, R. T. Geirsso and V.
Steinthorsdottir, “Paternity Change and the Recurrence
Risk in Familial Hypertensive Disorder in Pregnancy,”
Hypertens Pregnancy, Vol. 23, No. 2, 2004, pp. 219-225.
doi:10.1081/PRG-120037889
[16] Y. Yamanaka, K. Takeuchi, E. Konda, T. Samoto, A.
Satou, M. Mizudori and T. Maruo, “Transient Postpartum
Diabetes Insipidus in Twin Pregnancy Associated with
HELLP Syndrome,” Journal of Perinatal Medicine, Vol.
30, No. 3, 2002, pp. 273-275. doi:10.1515/JPM.2002.039
[17] I. Kalelioglu, A. Kubat Uzum, A. Yildirim and T. Okzam,
“Transient Gestational Diabetes Insipidus Diagnosed in
Successive Pregnancies: Review of Pathophysiology,
Diagnosis, Treatment, and Management of Delivery,” Pi-
tuitary, Vol. 10, No. 1, 2007, pp. 87-93.
doi:10.1007/s11102-007-0006-1